S&P 500 Healthcare Sector SEC Filings — August 05, 2026

Revenue grew 48% YoY to $23.0B, driven by Mounjaro (+91.2%) and Zepbound (+45.8%), with non-GAAP gross margin improving 130 bps to 86.3%

Net income surged 65.9% YoY to $2.375B, with diluted EPS up 65% to $4.37, while cost of sales declined 6.6% YoY, showing strong operational leverage

GAAP diluted EPS nearly tripled to $2.31 (up from $0.80), and full-year Adjusted EPS guidance raised to $7.90-$8.10, signaling a strong turnaround

CEO Mahoney Michael F bought $9M of stock at $48.33, a massive insider purchase indicating strong confidence in the company's prospects

Cash from operations improved sharply to $16.02B for H1 2026 from $4.75B a year ago, a 237% increase, providing ample firepower for R&D and M&A

Health Care Benefits segment MBR improved 250 bps YoY to 87.4%, and prior years' health care costs developed favorably by $1.2B, indicating better underwriting

Cash and cash equivalents rose to $13.989B from $9.129B at year-end 2025, a 53% increase, strengthening the balance sheet for potential acquisitions

Non-GAAP EPS guidance kept essentially flat at $35.50-$36.50 despite raised revenue guidance, as the $2.78 midpoint increase from business was fully offset by $3.03 in IPR&D charges

Director Habiger David C bought $50.1K of stock at $48.07, a smaller but still positive insider signal alongside the CEO's purchase

Days claims payable decreased 1.2 days QoQ to 41.7 days, potentially indicating faster claims processing or a shift in mix

Acquired IPR&D charges surged to $2.78B in Q2 2026 (vs $154M in Q2 2025), fully offsetting underlying business improvements and raising questions about M&A discipline

Outside the U.S., realized prices declined 36% primarily due to Mounjaro's addition to the NRDL in China, signaling pricing pressure in key international markets

Medical membership declined by 0.7 million to 26.0 million, indicating competitive losses in the health insurance segment

Faces headwinds from IRA-related provisions and a July MFN Letter, which could pressure drug pricing and margins in coming quarters

Verzenio revenue declined 1.0% YoY, and Trulicity grew only 11.7% in Q2, suggesting potential competitive pressure or market saturation in these franchises

Other comprehensive income swung from a gain of $213M in Q2 2025 to a loss of $13M in Q2 2026, indicating potential volatility in investment portfolio or hedging activities

Long-term debt increased to $47.86B from $40.87B, and short-term borrowings rose to $7.05B from $1.64B, increasing financial leverage

Other income swung to a loss of $73M from a $394M loss in the prior year quarter, though the improvement is notable, the continued loss is a drag on earnings

Total assets remained nearly flat at $253.8B, suggesting limited balance sheet growth despite revenue expansion

CEO's $9M open-market purchase at $48.33 is a strong vote of confidence; the stock may be undervalued relative to management's view

Mounjaro revenue grew 91.2% YoY to $9.94B, and Zepbound grew 45.8% to $4.93B; continued volume growth in GLP-1s provides a multi-year growth runway

With Adjusted EPS guidance raised to $7.90-$8.10 and cash flow from operations guided to at least $11.5B, the stock offers a potential value play with strong cash generation

With a 65.9% net income surge and cost of sales declining 6.6% YoY, the company is demonstrating operational efficiency that could drive further margin expansion

Non-GAAP gross margin improved 130 bps to 86.3%, and with raised revenue guidance of $85.0-$87.0B, the core business is exceptionally strong despite one-time charges

The Health Care Benefits segment MBR improved 250 bps YoY to 87.4%, and favorable prior-year development of $1.2B suggests underwriting improvements are sustainable

Cash and cash equivalents rose 53% to $13.989B, providing significant dry powder for bolt-on acquisitions or share buybacks

H1 2026 cash from operations of $16.02B (up 237% YoY) provides ample capacity to fund the $5.26B in property and equipment investments for manufacturing expansion

Director Habiger's purchase alongside the CEO's $9M buy creates a cluster of insider buying, often a precursor to positive catalysts

Eli Lilly's 48% revenue growth and Amgen's 9.5% growth highlight the GLP-1 class as the primary growth engine, while CVS Health's 7.3% growth reflects a more mature healthcare services model. The gap between pharma and services is widening.

Eli Lilly's $3.03 per share in IPR&D charges and Amgen's continued IRA headwinds show that while top-line growth is strong, bottom-line benefits are being partially offset by increased investment and regulatory costs.

Boston Scientific's CEO $9M purchase and director $57K purchase stand out as a strong bullish signal in a sector where insider buying has been sparse. This could indicate a perceived undervaluation.

CVS Health's MBR improvement of 250 bps and $1.2B in favorable prior-year development suggest the health insurance underwriting cycle is improving, which could benefit other managed care companies.

Eli Lilly's H1 cash from operations surged 237% to $16.02B, and CVS Health guided to at least $11.5B in operating cash flow, indicating strong cash generation across the sector that could support dividends, buybacks, and M&A.

Eli Lilly's 36% decline in realized prices outside the U.S. due to China's NRDL inclusion is a warning sign for other companies with international exposure, particularly in price-controlled markets.

Q3 2026 earnings call to assess whether IPR&D charges moderate and if Mounjaro/Zepbound volume growth continues; watch for any guidance revision on non-GAAP EPS [Ongoing]

Impact of IRA provisions and July MFN Letter on drug pricing; Q3 2026 results will show if cost of sales decline is sustainable [Next earnings: likely Oct 2026]

Medical membership trends and MBR trajectory; watch for any further decline in membership or deterioration in underwriting margins [Next earnings: likely Nov 2026]

CEO's $9M insider purchase is a strong signal; watch for any upcoming product approvals or earnings beats that could validate the insider buying [Next earnings: likely Oct 2026]

International pricing dynamics, especially in China and Europe; further price declines could pressure international revenue growth [Ongoing]

The 8-K filing was informational with no material data; watch for any subsequent filings that may provide business updates or guidance [Ongoing]

Impact of IRA drug price negotiations on Amgen and other companies with Medicare exposure; watch for any legislative developments [Ongoing]